Literature DB >> 17028546

[Multiple gliomas: clinical studies and pathophysiological hypothesis].

K Auré1, F Laigle-Donadey, G Kaloshi, A Amiel-Benouaich, M Sanson.   

Abstract

INTRODUCTION: Although a rare entity, multiple gliomas must be recognized and distinguished from other causes of multiple brain lesions.
METHODS: Clinical and radiological features of 33 multiple gliomas were reviewed, including 20 synchronous cases and 13 metachronous cases.
RESULTS: In 17 patients, radiological features were highly suggestive of spread from a primary site (multifocal gliomas). No apparent dissemination route was identified in the other cases which were presumed to be multicentric gliomas. For nine patients (27 percent), a second neoplasia or cancer was found in first degree relatives suggesting a genetic predisposition. Overall median survival was 79 weeks (64 weeks for glioblastomas). The age at onset was the main prognostic factor.
CONCLUSION: Multiple gliomas represent a heterogeneous entity, probably corresponding to different mechanisms. In our group, survival was comparable to unique glioma.

Entities:  

Mesh:

Year:  2006        PMID: 17028546     DOI: 10.1016/s0035-3787(06)75088-3

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  2 in total

Review 1.  Dysphasia and phantosmia as first presentation of multifocal cerebral anaplastic astrocytomas: case report and review of the literatures.

Authors:  Xiangyi Kong; Yu Wang; Shuai Liu; Zhaohui Lu; Huanwen Wu; Xinxin Mao; Xin Cheng; Jun Gao; Jian Guan; Yi Yang; Yongning Li; Bing Xing; Wenbin Ma; Renzhi Wang
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

2.  Characteristics of gliomas in patients with somatic IDH mosaicism.

Authors:  Charlotte Bonnet; Laure Thomas; Dimitri Psimaras; Franck Bielle; Elodie Vauléon; Hugues Loiseau; Stéphanie Cartalat-Carel; David Meyronet; Caroline Dehais; Jérôme Honnorat; Marc Sanson; François Ducray
Journal:  Acta Neuropathol Commun       Date:  2016-03-31       Impact factor: 7.578

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.